HIV and Multi-Drug Resistant Tuberculosis: a Study on Clinical Outcomes

November 1, 2024 updated by: Hamidreza Kouhpayeh, Zahedan University of Medical Sciences

HIV Infection Accompanied by Multi-Drug Resistant Tuberculosis: a Decadal Systematic Review and Meta-Analysis

This study aims to investigate the relationship between HIV infection and multi-drug resistant tuberculosis (MDR-TB) among affected individuals in Zahedan, Iran. It will involve a detailed analysis of patient demographics, clinical characteristics, and treatment outcomes to enhance understanding of this co-infection. The findings may inform better treatment strategies and healthcare policies for managing these diseases in similar populations.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

222128

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Iran, Islamic Republic of
    • Sistan and Baluchestan
      • Zahedan, Sistan and Baluchestan, Iran, Islamic Republic of, 98167-43463
        • Zahedan University of Medical Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population consists of adult individuals (aged 18 years and older) diagnosed with both HIV infection and multi-drug-resistant tuberculosis (MDR-TB). This meta-analysis synthesizes data from various studies conducted across multiple countries, including Brazil, the USA, Canada, India, Ethiopia, and several others. The population includes a diverse cohort of patients, reflecting various demographic characteristics such as age, sex, and geographical location.

The studies included in this meta-analysis feature participants with confirmed diagnoses of HIV and MDR-TB, with a focus on understanding the co-infection dynamics, treatment outcomes, and associated health challenges. Data extraction from these studies provides insight into the prevalence and impact of MDR-TB among HIV-positive patients, highlighting the importance of tailored

Description

Inclusion Criteria:

  • Adults (aged 18 years and older) diagnosed with both HIV and multi-drug-resistant tuberculosis (MDR-TB).
  • Studies published in peer-reviewed journals.
  • Studies that provide data on the co-occurrence of HIV and MDR-TB.
  • Participants from diverse geographical regions to enhance generalizability.
  • Studies with clear definitions of MDR-TB according to WHO guidelines.

Exclusion Criteria:

  • Studies that focus solely on drug-susceptible tuberculosis without MDR-TB.
  • Studies involving pediatric populations (under 18 years of age).
  • Non-original research such as reviews, editorials, and commentaries.
  • Studies lacking sufficient data on the co-occurrence of HIV and MDR-TB.
  • Studies that do not adhere to ethical guidelines for human subjects or lack appropriate ethical approvals.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of Multi-Drug Resistant Tuberculosis (MDR-TB) in HIV-Positive Patients
Time Frame: Data collected over the course of the studies from 2006 to 2018.
This study aims to determine the prevalence of multi-drug resistant tuberculosis (MDR-TB) among patients co-infected with HIV. Data will be collected from various studies included in the meta-analysis, focusing on the incidence rates of MDR-TB in this population. The analysis will provide insights into the challenges faced in treating HIV-positive individuals with MDR-TB and highlight the need for targeted interventions.
Data collected over the course of the studies from 2006 to 2018.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zahedan University of Medical Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 15, 2024

Primary Completion (Actual)

August 22, 2024

Study Completion (Actual)

September 3, 2024

Study Registration Dates

First Submitted

November 1, 2024

First Submitted That Met QC Criteria

November 1, 2024

First Posted (Estimated)

November 4, 2024

Study Record Updates

Last Update Posted (Estimated)

November 4, 2024

Last Update Submitted That Met QC Criteria

November 1, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HIVTB2024

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV Infection

Clinical Trials on Examination of HIV Infection in Patients with Multi-Drug Resistant Tuberculosis (MDR-TB)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe